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Abstract
Background: Epithelial cell adhesion molecule (EpCAM) is a promising biomarker for squamous cell carcinoma
(SCC) of the uterine cervix, because it is over-expressed in various cancers of epithelial origin. However, EpCAM
expression reported in previous immunohistochemistry (IHC) studies was inconsistent. We hypothesize that the
membrane-distal part of EpCAM may be lost during tissue preparation, leaving only the membrane-proximal part of
EpCAM available for antibody binding and IHC staining.
Methods: Two new anti-EpCAM MAbs to the membrane-proximal part (WC-2) and the membrane-distal part (WC-
1) of EpCAM were generated and characterized. WC-2 was selected for its ability to detect EpCAM in cervical tissues
by IHC. One hundred thirty-five archival paraffin-embedded tissues previously diagnosed as cervical SCC (n=44),
high-grade (HSIL) (n=43), or low-grade (LSIL) (n=48) squamous intraepithelial lesions were examined. IHC score was
collected, recorded, and analyzed for distribution, intensity, and percentage of cancer cells stained for EpCAM.
Results: EpCAM expression was consistently detected on cervical tissues by WC-2, but not by WC-1. EpCAM was
expressed with high IHC score in the majority of cervical SCC (37/44), but not in normal epithelial area adjacent to
SCC. EpCAM was also highly expressed on precancerous lesion of the cervix, particularly in HSIL. More importantly,
EpCAM expression could be used to distinguish between HSIL and LSIL, according to staining distribution. HSIL
tissues displayed EpCAM expression in two-thirds to full thickness of the epithelium, while in LSIL the staining was
limited to the lower one-third of the thickness. The IHC score of EpCAM expression was strongly correlated with
cervical cancer and grades of precancerous lesions (r=0.875, p<0.001).
Conclusion: Only the anti-EpCAM MAb to the membrane-proximal part is able to detect EpCAM on paraffin-
embedded cervical cancer tissues. A strong positive correlation between EpCAM expression level and the grades of
SILs provides the possibility that EpCAM can be used to predict prognosis and severity in these patients.
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Background
Epithelial cell adhesion molecule is a cell-surface glyco-
protein that is over-expressed in various cancers of epi-
thelial origin. However, EpCAM expression investigated
by immunohistochemistry (IHC) in squamous cell
carcinoma (SCC) of the uterine cervix showed hetero-
geneity [1–6]. A study by Went, et al. [4] that used anti-
EpCAM (VU-1D9) antibody reported EpCAM expres-
sion on only 17 of 42 SCC in paraffin embedded-tissues
with moderate to high intensity. Using another anti-
EpCAM (323/A3) antibody, Litvinov, et al. [5] reported
EpCAM expression on cryostat sections of cervical SCC
and cervical intraepithelial neoplasia (n = 15 and n = 39,
respectively). EpCAM was occasionally detected at low
intensity in the basal layer of normal ectocervical epithe-
lia. However, the original publication that described 323/
A3 antibody reported that EpCAM was not expressed
on formalin-fixed, paraffin-embedded cervical SCC tis-
sues [6]. Another 3 studies that used paraffin-embedded
tissues reported that EpCAM expression was not de-
tected on cervical SCC, although anti-EpCAM antibody
clones were not mentioned in these studies [1–3]. Based
on the aforementioned studies, we speculate that
EpCAM expression is inconsistently detected on
formalin-fixed, paraffin-embedded tissues, as compared
to consistent detection observed in cryostat frozen sec-
tions. This difference in detection consistency may be
due to the loss of the membrane-distal part of EpCAM
molecule during tissue preparation for IHC.
When EpCAM is expressed on the surface of cancer
cells, it can be cleaved by a variety of proteases, includ-
ing trypsin, at the position Arginine80/Arginine81
(Fig. 1). This cleavage creates two fragments – 6 kDa
and 32 kDa. The 6 kDa fragment is located distant from
the cell membrane, whereas the 32 kDa fragment is lo-
cated proximal to the membrane (Fig. 1). The fragments
that are still held together by the disulfide bond between
cysteine66 and cysteine99 after cleavage may be broken
when exposed to reducing agents [7, 8]. During tissue
preparation for IHC staining, the distal fragment of
EpCAM can be removed by proteolytic enzymes, such
as trypsin or pronase, during the antigen retrieval
process. The anti-EpCAM antibodies used in previous
studies, including VU-1D9 and 323/A3, recognized the
6 kDa fragment [6, 9, 10].
In this study, anti-EpCAM monoclonal antibodies that
recognize the 6 kDa or the 32 kDa fragment of EpCAM
extracellular domain were generated and compared to
facilitate detection of EpCAM expression in cervical
SCC. The antibody that exhibited intense IHC staining
on cervical SCC with no background staining on normal
tissue was then used to evaluate EpCAM as a biomarker
on cancerous and precancerous lesions of the cervix.
Methods
Generation of anti-EpCAM monoclonal antibodies
Anti-EpCAM monoclonal antibodies were generated by
hybridoma technique. The protocol for the mouse ex-
periments was approved by Siriraj Animal Care and Use
Committee (SiACUC), Faculty of Medicine Siriraj
Hospital, Mahidol University (007/2554). BALB/c mice
(National Laboratory Animal Center, Nakhon Pathom,
Thailand) were immunized intraperitoneally with 50 μg
of purified recombinant EpCAM protein corresponding
to amino acid 24–266 of human EpCAM extracellular
domain (Sino Biological, Inc., Beijing, P.R. China) in
complete Freund’s adjuvant (Sigma-Aldrich, St. Louis,
MO, USA). The mice were boosted with 50 μg of the
same antigen in incomplete Freund’s adjuvant (Sigma-
Aldrich, St. Louis, MO, USA) twice at a 4-week interval.
A final boost with 50 μg of the same antigen in PBS by
intravenous injection was performed 3 days before the
mice were sacrificed. For hybridoma production, the
spleen was collected aseptically and ground to separate
Fig. 1 Diagram of EpCAM molecule presenting anti-EpCAM antibody recognition sites. 1–314: amino acid residue; cys: cysteine; WC-1, WC-2, VU-1D9,
323/A3, MOC-31, and Ber-Ep4: names of MAb; *MAbs produced in this study
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spleen cells for fusion with myeloma cells P3-X63-
Ag8.653. Hybridoma cells secreting anti-EpCAM anti-
bodies were screened by ELISA using purified recombin-
ant extracellular domain of human EpCAM as antigen.
The hybridoma cells that secreted anti-EpCAM antibody
were sub-cloned using limiting dilution method to ob-
tain the monoclonal hybridomas. Monoclonal antibodies
were then purified from cell culture supernatant using
Protein G-Sepharose® affinity chromatography (GE
Healthcare, Uppsala, Sweden).
SDS-PAGE and western blot analysis
HT29 cells (EpCAM-positive cell line) were trypsinized
and lysed in lysis buffer (1% triton X-100, 1 mM CaCl2,
50 mM Tris, pH 7.4). The lysate was then separated in
12% SDS-PAGE gel with or without 2-mercaptoethanol
(reducing or non-reducing condition, respectively), and
transferred to nitrocellulose membranes (Sartorious,
Goettingen, Germany). The membrane was blocked and
incubated with anti-EpCAM antibody at room
temperature for 1 h. HRP-conjugated goat anti-mouse
IgG (KPL, Inc. Gaithersburg, MD, USA) was used as sec-
ondary antibody. The signal was developed with ECL
substrate (ThermoFisher Scientific, Waltham, MA, USA)
and the image was captured by a Syngene gel documen-
tation system (Syngene, Cambridge, UK).
Tissue specimens
The protocol for this study was approved by Ethics
Committee for Research in Humans, Faculty of Medi-
cine Siriraj Hospital, Mahidol University (EC1260). One
hundred and thirty-five archival paraffin-embedded tis-
sues, previously diagnosed as cervical squamous cell car-
cinoma (SCC) (n = 44), high-grade (HSIL) (n = 43), or
low-grade (LSIL) (n = 48) squamous intraepithelial le-
sions were included. Morphologically normal epithelia
adjacent to the areas of SCC or SILs were identified in
54 tissues. All slides were stained by hematoxylin and
eosin (H&E) and reviewed to confirm diagnosis.
Immunohistochemistry (IHC) staining
The 5 μm thick paraffin-embedded tissue sections were
cut onto poly-L-lysine-coated microscope slides (Ther-
moFisher Scientific, Waltham, MA, USA), deparaffi-
nized, and rehydrated. Sections were incubated for
20 min at 95 °C with 0.01 M citrate buffer (pH 6.0) for
antigen retrieval. Sections were stained using an auto-
stainer (DAKO, Glostrup, Denmark) with 2 μg/ml of
anti-EpCAM antibody for 30 min at RT. Sections were
then incubated for 1 h at RT with HRP-conjugated goat
anti-mouse IgG secondary antibody (DAKO, Glostrup,
Denmark) and developed for 5 min with 3,3-diamino-
benzidine (ThermoFisher Scientific, Waltham, MA,
USA), followed by counterstaining using hematoxylin.
Colon cancer tissue sections known to express EpCAM
were used as a positive control in each batch of IHC
staining.
IHC scores
EpCAM expression was analyzed using 3 criteria, in-
cluding staining distribution (A), staining intensity
(B), and percentage of EpCAM positive cells (C).
Staining distribution (A) was scored as: basal layer =
0, up to 1/3 of epithelium = 1, up to 2/3 of epithe-
lium = 2, full thickness = 3. Staining intensity (B) was
scored as: no staining = 0, weak intensity = 1, moder-
ate intensity = 2, strong intensity = 3. Percentage of
EpCAM positive cells (C) was scored as: 0–10% = 0,
11–40% = 1, 41–70% = 2, 71–100% = 3. Final IHC
scores were calculated by the formula: IHC score =
A × B × C. EpCAM expression levels were graded by
IHC scores and divided into one of four groups, as
follows: high (score = 18–27), medium (score = 6–12),
low (score = 1–4) level, or no expression (score = 0).
Statistical analysis
Predictive Analytics Software version 18.0 (SPSS,
Inc., Chicago, IL, USA) was used for statistical ana-
lysis. Spearman correlation was used to analyze asso-
ciations between IHC scores and grades of tissue
abnormality.
Results
Anti-EpCAM WC-1 and WC-2 monoclonal antibodies and
their recognition sites
The monoclonal antibodies directed against EpCAM
extracellular domain were selected from a panel of
monoclonal antibodies generated in our laboratory. The
strategy for selection included ELISA using purified re-
combinant EpCAM extracellular domain. Sixteen hy-
bridoma clones demonstrated strong reactivity with the
recombinant EpCAM extracellular domain by ELISA.
Two anti-EpCAM antibody clones, namely WC-1 and
WC-2, were selected because they produced the stron-
gest reactivity to the recombinant protein.
The recognition sites of WC-1 and WC-2 antibodies
were analyzed by Western blot. The results showed that
WC-2 recognized the 32 kDa and 38 kDa fragments
under reducing condition, as shown in Fig. 2. The band
of 38 kDa was still present because of the partial cleav-
age of EpCAM. In contrast, WC-1 antibody did not
recognize the band of 32 kDa, but recognized the
38 kDa fragment. The commercial VU-1D9 anti-
EpCAM antibody, which is known to recognize the epi-
tope on 6 kDa fragment, showed the same pattern as
WC-1.
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The ability of WC-1 and WC-2 to detect EpCAM in
paraffin-embedded cervical cancer tissues by IHC staining
Both WC-1 and WC-2 were further tested regarding
their ability to detect EpCAM by IHC staining using
paraffin-embedded cervical SCC tissue. Only WC-2 anti-
body exhibited particularly intense IHC staining on cer-
vical SCC with no background staining on adjacent
normal tissue (Fig. 3g-h, 3a-b, respectively). EpCAM
staining by WC-2 demonstrated a cell-surface membran-
ous staining pattern, and also a cytoplasmic pattern in
some cells (as shown in Fig. 4 which represents a higher
magnification of Fig. 3e).
In comparison with commercial anti-EpCAM anti-
bodies, IHC staining using Ber-Ep4 or MOC-31, anti-
bodies directed against 6 kDa fragment that are widely
used for IHC [10, 11], were studied in 6 SCC tissue
specimens that had intense EpCAM staining by WC-2.
Some tissues had weakly positive staining with patchy
distribution, in 1/6 and 4/6 by Ber-Ep4 and MOC-31
antibodies, respectively.
EpCAM expression in cancer and precancer of the uterine
cervix using WC-2
EpCAM expression on cervical tissues was analyzed in
detail by IHC using WC-2 and was recorded in 3 cat-
egories, including staining distribution, staining inten-
sity, and percentage of EpCAM positive cells (Table 1).
The IHC staining pattern in SCC tissues demonstrated
that, on the majority of SCC tissues (39/44), the full
thickness of the epithelium was positive for EpCAM ex-
pression with moderate to intense intensity (Fig. 3g-h).
In contrast, the ectocervical epithelium from noncancer-
ous tissue or morphologically normal epithelium adja-
cent to the areas of SCC was negative for EpCAM.
Weak staining was occasionally found on the basal layer
(Fig. 3a-b).
Fig. 2 Western blot analysis of WC-1, WC-2, and VU-1D9 antibodies, showing that WC-2 recognized a 32 kDA proximal extracellular fragment of
EpCAM molecule. Abbreviations: M, protein marker; NR, non-reducing condition; R, reducing condition
Fig. 3 Immunohistochemistry staining of EpCAM using WC-2 antibody (a, c, d, g) and hematoxylin and eosin (H&E) staining (b, d, f, h) of ectocervical
tissues. a, b normal ectocervical epithelium; c, d low-grade squamous intraepithelial lesion (LSIL); e, f high-grade squamous intraepithelial lesion (HSIL);
g, h SCC of the uterine cervix
Chantima et al. BMC Cancer  (2017) 17:811 Page 4 of 7
EpCAM expression was also investigated on speci-
mens with precancerous lesions of the uterine cervix, in-
cluding high-grade (HSIL) and low-grade (LSIL)
squamous intraepithelial lesions. In the majority of
HSILs, EpCAM expression was positive up to two-thirds
or full thickness of the epithelium with moderate to in-
tense intensity (Fig. 3e-f ). In LSILs, EpCAM was found
on the lower one-third of the epithelium with weak to
moderate intensity (Fig. 3c-d).
EpCAM expression levels were further graded into
IHC scores and divided into groups as high (score = 18–
27), medium (score = 6–12), low (score = 1–4), or no ex-
pression (score = 0) (Table 2). EpCAM expression level
was high on the majority of cervical tissues with SCC
(37/44) and HSIL (33/43), with low level (22/48) to
medium level (21/48) expression observed on tissues
with LSIL. EpCAM expression was not detected (50/54)
or detected weakly (4/54) on normal cervical tissues. A
strong positive correlation was found between levels of
EpCAM expression and SCC, and grades of SILs (Spear-
man’s correlation r = 0.875, p < 0.001).
Discussion
In this study, we revealed that EpCAM expression can
be consistently detected in paraffin-embedded cervical
SCC tissues using a novel WC-2 antibody that recog-
nized the 32 kDa fragment of EpCAM extracellular do-
main. In contrast, other anti-EpCAM antibodies that
Fig. 4 High-power magnification of Fig. 3e. EpCAM staining in abnormal squamous epithelium by WC-2 showed a cell-surface membranous staining
pattern, and also a cytoplasmic pattern in some cells
Table 1 EpCAM expression pattern, including staining distribution, staining intensity, and percentage of EpCAM positive cells, in
SCC, HSIL, and LSIL of the uterine cervix
Specimen group r p-value
SCC (n = 44) HSIL (n = 43) LSIL (n = 48) Normal (n = 54)
n (%) n (%) n (%) n (%)
Staining distribution
Full thickness 39 (88.6%) 29 (67.4%) 4 (8.3%) 0 (0%) 0.890 <0.001
Up to 2/3 of epithelium 5 (11.4%) 13 (30.2%) 10 (20.8%) 0 (0%)
Up to 1/3 of epithelium 0 (0%) 1 (2.3%) 32 (66.7%) 4 (7.4%)
Basal layer 0 (0%) 0 (0%) 1 (2.1%) 50 (92.6%)
No staining 0 (0%) 0 (0%) 1 (2.1%) 0 (0%)
Staining intensity
Intense 29 (65.9%) 23 (53.5%) 0 (0%) 1 (1.9%) 0.698 <0.001
Moderate 14 (31.8%) 17 (39.5%) 29 (60.4%) 15 (27.8%)
Weak 1 (2.3%) 3 (7.0%) 18 (37.5%) 38 (70.4%)
No staining 0 (0%) 0 (0%) 1 (2.1%) 0 (0%)
% of EpCAM positive cells
71–100% 38 (86.4%) 38 (88.4%) 21 (43.8%) 21 (38.9%) 0.436 <0.001
41–70% 5 (11.4%) 5 (11.6%) 22 (45.8%) 25 (46.3%)
11–40% 1 (2.3%) 0 (0%) 4 (8.3%) 8 (14.8%)
0–10% 0 (0%) 0 (0%) 1 (2.1%) 0 (0%)
p-value < 0.001 indicates statistical significance
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recognize the 6 kDa fragment cannot detect EpCAM ex-
pression. These findings support our hypothesis that the
32 kDa membrane-proximal fragment of EpCAM, but
not the 6 kDa distal part, is preserved on paraffin-
embedded tissues, and enables IHC staining of cervical
cancer tissues. Anti-EpCAM antibodies against the
32 kDa fragment are more suitable for IHC staining. Al-
though, a number of monoclonal antibodies to the
32 kDa fragment have been reported [9, 10, 12, 13], they
were never used to study EpCAM expression in cervical
cancer.
The present study strongly demonstrated that EpCAM
expression was detected on the tissues of cervical SCC
and precancerous SILs, and the expression levels corre-
lated with grades of cell abnormality. Our results are in
complete agreement with those of an earlier preliminary
study by Litvinov, et al. [5] that studied the 323/A3 anti-
EpCAM antibody using cryostat sections. We also found
a statistically significant correlation between the levels of
EpCAM expression and grades of cervical intraepithelial
abnormality (correlation coefficient = 0.875, p < 0.001).
Recent studies have reported that several biomarkers
can be used for cervical SCC, including Ki67 and
p16INK4A [14–16]. However, the expression of bio-
markers is limited to the nucleus and cytoplasm of cer-
vical cancer cells. To date, no cell-surface biomarker has
been described for cervical SCC. The advantage of cell-
surface biomarker is that it can be a target in immunodi-
agnostics or immunotherapy. For example, human
epidermal growth factor receptor-2 (HER2/neu) is a tar-
get for antibody that exhibited therapeutic efficacy in
metastatic and early-stage breast cancers [17, 18]. More-
over, human carcinoembryonic antigen (CEA) is a target
in colorectal cancer immunotherapy [19, 20]. Here, we
report that all cervical SCC tissues demonstrated
EpCAM expression and this evidence supports that
EpCAM can be a cell-surface biomarker for cervical
SCC.
An important property of biomarker for cervical
cancer is the ability to detect and differentiate be-
tween HSIL and LSIL at precancerous stages. This
information can be used to aid in the diagnosis and
in treatment planning. LSIL lesion has high regression
rate, while HSIL has low rate of spontaneous regres-
sion and a substantial risk of developing into invasive
cancer. Histologic differentiation between LSIL and
HSIL is essential, as HSIL diagnosed on cervical bi-
opsy requires excision or diagnostic excisional proced-
ure, such as conization or loop electrosurgical
excision procedure (LEEP) [21]. Analysis of our data
indicated that EpCAM expression could distinguish
between HSIL and LSIL by the staining distribution.
HSIL tissues (42/43) displayed EpCAM expression in
two-thirds to full thickness of the epithelium, while
EpCAM staining in tissues with LSIL was limited to
the lower one-third of epithelial thickness (34/48).
Moreover, a strong positive correlation between
EpCAM expression level and grades of SILs suggests
the possibility that EpCAM can be used to predict
prognosis and severity in patients.
Conclusions
We report here for the first time that the membrane-
proximal fragment of EpCAM extracellular domain is
preserved on paraffin embedded-tissues and that it is re-
quired for IHC staining. This study also presents strong
evidence that EpCAM expression is a suitable biomarker
for cancer and precancerous lesions of the uterine
cervix.
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